| Mrs Monica Neal Davis, MA,CCC-SLP | |
|
70 N. Broadway, Akron, OH 44308-1911 | |
| (330) 761-1661 | |
| Not Available |
| Full Name | Mrs Monica Neal Davis |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 70 N. Broadway, Akron, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235556689 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP.4932 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Monica Neal Davis, MA,CCC-SLP 1770 Olalla Ave, Akron, OH 44305-4519 Ph: () - | Mrs Monica Neal Davis, MA,CCC-SLP 70 N. Broadway, Akron, OH 44308-1911 Ph: (330) 761-1661 |
News Archive
According to the Mayo Clinic, about 20% of breast cancers make abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2).
Watson Pharmaceuticals, Inc. today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million or $1.09 per diluted share, compared to $105.9 million or $0.85 per diluted share in the third quarter 2010.
Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation, today announced the initial development and successful testing of a novel integrated light source architecture for OCT imaging. Axsun believes this proprietary optical engine design raises the bar on imaging speed and overcomes fundamental limitations of laser-based designs for swept source OCT light sources.
POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.
SironRX Therapeutics Inc., a privately-held, clinical-stage biotechnology company developing novel regenerative therapies to prevent scarring and promote dermal wound repair, is pleased to report that it has completed enrollment of patients in Cohort 1 of its placebo-controlled, randomized, dose escalation double-blind clinical study evaluating the safety and efficacy of JVS-100 to reduce scar formation and improve wound healing in patients receiving surgical sternotomy incisions.
› Verified 8 days ago
Michele Y Gunther, S.P.L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Jamie Blaylock, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 450 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-376-0153 | |
Kimberly Marie Gibbons, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2425 Foxboro Ave, Akron, OH 44305 Phone: 330-631-5678 | |
Kristin Weaver, M.A. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 640 W Market St, Akron, OH 44303 Phone: 330-762-5425 | |
Mrs. Elizabeth Kinzig, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 Wyant Rd, Akron, OH 44313 Phone: 330-836-7953 | |
Mrs. Andrea P. Brewer, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 181 Polsky Building, Akron, OH 44325 Phone: 330-972-8189 Fax: 330-972-7884 | |
Mary Mariani-walker, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1199 Vernon Odom Blvd, Akron, OH 44307 Phone: 330-873-3396 |